[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652890":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":43,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":53,"maxAge":10,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":10,"overallStatus":61,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"surufatinib",null,"Surufatinib therapy",[13],"Drug: Surufatinib Administration",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Surufatinib Administration","Surufatinib as monotherapy or combination therapy, at the discretion of the investigator based on the patient's overall condition.",[9],[21],{"name":22,"affiliation":5,"role":23},"Feng Ye","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","+86-592-2137569","yefengdoctor@sina.com",[30],{"facility":5,"status":10,"city":31,"state":32,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Xiamen","Fujian","China","CN",{"type":36,"coordinates":37},"Point",[38,39],118.08187,24.47979,{"lat":39,"lon":38},[42],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},{"type":44,"investigatorFullName":45,"investigatorTitle":5,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Yefeng","100652890","real-world-study-of-the-safety-and-efficacy-of-surufatinib-in-the-treatment-of-neuroendocrine-tumors-100652890",false,"NCT07780539","Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors","Inclusion Criteria:\n\n* Patients with pathologically or cytologically confirmed neuroendocrine tumors;\n* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;\n* Life expectancy ≥ 12 weeks;\n* Adequate organ and bone marrow function\n\nExclusion Criteria:\n\n* Participation in other drug clinical trials with investigational drug treatment within the past 4 weeks;\n* History of other malignancies within the past 5 years, except for curatively resected basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ;\n* Patients with contraindications to surufatinib (e.g., active bleeding, ulcer, intestinal perforation, intestinal obstruction, medically uncontrolled hypertension, grade III-IV cardiac dysfunction, within 30 days after major surgery, severe hepatic or renal impairment, etc.);\n* Presence of any disease or condition that affects drug absorption, or inability to take surufatinib orally;\n* Any condition deemed by the investigator as unsuitable for study drug treatment.","ALL","18 Years",{"count":55,"type":56},60,"ESTIMATED","OBSERVATIONAL","Prior clinical trials have demonstrated promising efficacy and manageable safety of surufatinib in neuroendocrine tumors (NETs). This real-world study aims to evaluate the clinical efficacy and safety of surufatinib in patients with NETs, providing additional real-world evidence to support clinical application, guide novel therapeutic strategies, and ultimately improve patient outcomes.",[60],"Neuroendocrine (NE) Tumors","NOT_YET_RECRUITING","2026-08-19",{"date":64,"type":65},"2026-08-21","ACTUAL",{"date":67,"type":56},"2026-09-01",{"date":69,"type":56},"2031-08-31",{"name":45,"class":6},1]